KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) EBITDA (2016 - 2025)

Historic EBITDA for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $6.5 billion.

  • Pfizer's EBITDA rose 286.44% to $6.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $22.8 billion, marking a year-over-year increase of 3044400.0%. This contributed to the annual value of $17.8 billion for FY2024, which is 18689.98% up from last year.
  • Latest data reveals that Pfizer reported EBITDA of $6.5 billion as of Q3 2025, which was up 286.44% from $5.1 billion recorded in Q2 2025.
  • Pfizer's EBITDA's 5-year high stood at $13.0 billion during Q3 2022, with a 5-year trough of -$14.1 billion in Q4 2023.
  • Its 5-year average for EBITDA is $3.5 billion, with a median of $5.5 billion in 2021.
  • In the last 5 years, Pfizer's EBITDA crashed by 16739.68% in 2023 and then soared by 42644.16% in 2024.
  • Quarter analysis of 5 years shows Pfizer's EBITDA stood at $7.9 billion in 2021, then skyrocketed by 30.62% to $10.3 billion in 2022, then plummeted by 236.89% to -$14.1 billion in 2023, then soared by 144.61% to $6.3 billion in 2024, then rose by 2.86% to $6.5 billion in 2025.
  • Its EBITDA stands at $6.5 billion for Q3 2025, versus $5.1 billion for Q2 2025 and $5.0 billion for Q1 2025.